Valeant Slumps as New CEO Faulted by Successor at Perrigo

  • Perrigo’s new CEO calls recent track record ‘unacceptable’
  • Papa hired to improve Valeant’s fortunes after missteps

Shares of Valeant Pharmaceuticals International Inc. fell 5.4 percent after the past performance of its new chief executive officer, Joseph Papa, was criticized by the CEO who succeeded him at his previous company.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.